Current Problems in Surgery
Volume 43, Issue 7 , Pages 462-551 , July 2006

Neoadjuvant Therapy in the Treatment of Solid Tumors

  • Christopher A. Garces, MD

      Affiliations

    • Resident in General Surgery, University of Florida College of Medicine, Gainesville, Florida
    • ,
  • Priscilla F. McAuliffe, MD, PhD

      Affiliations

    • Resident in General Surgery, University of Florida College of Medicine, Gainesville, Florida
    • ,
  • Steven N. Hochwald, MD

      Affiliations

    • Assistant Professor of Surgery, Chief, Division of Surgical Oncology and Endocrine Surgery, University of Florida College of Medicine, Gainesville, Florida
    • ,
  • William G. Cance, MD

      Affiliations

    • Professor and Chairman of Surgery, University of Florida College of Medicine, Gainesville, Florida

References 

  1. Frei E . Clinical cancer research (an embattled species) . Cancer . 1982;50(10):1979–1992
  2. Cormier JN , Langstein HN , Pisters PW . Preoperative therapy for soft tissue sarcoma . Cancer Treat Res . 2004;120:43–63
  3. Issels RD , Schlemmer M . Current trials and new aspects in soft tissue sarcoma of adults . Cancer Chemother Pharmacol . 2002;49(Suppl 1):S4–S8
  4. Phan A , Patel S . Advances in neoadjuvant chemotherapy in soft tissue sarcomas . Curr Treat Options Oncol . 2003;4:433–439
  5. Gortzak E , Azzarelli A , Buesa J , et al.   A randomised phase II study on neo-adjuvant chemotherapy for “high-risk” adult soft-tissue sarcoma . Eur J Cancer . 2001;37:1096–1103
  6. Schabel FM . Concepts for treatment of micrometastases developed in murine systems . Am J Roentgenol . 1976;126:500–511
  7. Griswold DP , Corbett TH . Breast tumor modeling for prognosis and treatment . Recent Results Cancer Res . 1976;57:42–58
  8. Corbett TH , Griswold DP , Roberts BJ , et al.   Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy . Cancer Treat Rep . 1978;62:1471–1488
  9. Simpson-Herren L , Sanford AH , Holmquist JP . Effects of surgery on the cell kinetics of residual tumor . Cancer Treat Rep . 1976;60:1749–1760
  10. Corbett TH , Roberts BJ , Leopold WR , et al.   Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice . Cancer Res . 1984;44:717–726
  11. Fisher B , Gunduz N , Saffer EA . Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases . Cancer Res . 1983;43:1488–1492
  12. Gunduz N , Fisher B , Saffer EA . Effect of surgical removal on the growth and kinetics of residual tumor . Cancer Res . 1979;39:3861–3865
  13. Fichtner I , Tanneberger S . Preoperative (neoadjuvant) chemotherapy in the murine Lewis lung carcinoma and possible implications for clinical use . Anticancer Res . 1987;7:227–233
  14. Landis SH , Murray T , Bolden S , Wingo PA . Cancer statistics, 1999 . CA Cancer J Clin . 1999;49:8–31 1
  15. Veronesi U , Saccozzi R , Del Vecchio M , et al.   Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast . N Engl J Med . 1981;305:6–11
  16. Fisher B , Bauer M , Margolese R , et al.   Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer . N Engl J Med . 1985;312:665–673
  17. Fisher B , Jeong JH , Anderson S , et al.   Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation . N Engl J Med . 2002;347:567–575
  18. Bonadonna G . Evolving concepts in the systemic adjuvant treatment of breast cancer . Cancer Res . 1992;52:2127–2137
  19. Bonadonna G , Brusamolino E , Valagussa P , et al.   Combination chemotherapy as an adjuvant treatment in operable breast cancer . N Engl J Med . 1976;294:405–410
  20. Bonadonna G , Valagussa P , Moliterni A , et al.   Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer (the results of 20 years of follow-up) . N Engl J Med . 1995;332:901–906
  21. Bonadonna G , Zambetti M , Valagussa P . Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results . JAMA . 1995;273:542–547
  22. Bonadonna G , De Lena M , Brambilla C , et al.   Combination chemotherapy and combined treatment modality in disseminated and locally advanced breast cancer . Prog Clin Biol Res . 1977;12:437–458
  23. De Lena M , Zucali R , Viganotti G , et al.   Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer . Cancer Chemother Pharmacol . 1978;1:53–59
  24. Bonadonna G , Valagussa P , Zucali R , Salvadori B . Primary chemotherapy in surgically resectable breast cancer . CA Cancer J Clin . 1995;45:227–243
  25. Bonadonna G , Valagussa P , Brambilla C , et al.   Primary chemotherapy in operable breast cancer (eight-year experience at the Milan Cancer Institute) . J Clin Oncol . 1998;16:93–100
  26. Hortobagyi GN , Spanos W , Montague ED , et al.   Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy . Int J Radiat Oncol Biol Phys . 1983;9:643–650
  27. Hortobagyi GN , Gutterman JU , Blumenschein GR , et al.   Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG . Cancer . 1979;43:1225–1233
  28. Hortobagyi GN , Frye D , Buzdar AU , et al.   Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma . Cancer . 1989;63:37–45
  29. Kuerer HM , Newman LA , Smith TL , et al.   Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy . J Clin Oncol . 1999;17:460–469
  30. Cance WG , Carey LA , Calvo BF , et al.   Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma (effective clinical downstaging allows breast preservation and predicts outstanding local control and survival) . Ann Surg . 2002;236:295–302 discussion 302-3.
  31. Fisher B , Brown A , Mamounas E , et al.   Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer (findings from National Surgical Adjuvant Breast and Bowel Project B-18) . J Clin Oncol . 1997;15:2483–2493
  32. van der Hage JA , van de Velde CJ , Julien JP , et al.   Preoperative chemotherapy in primary operable breast cancer (results from the European Organization for Research and Treatment of Cancer trial 10902) . J Clin Oncol . 2001;19:4224–4237
  33. Trock BJ , Leonessa F , Clarke R . Multidrug resistance in breast cancer (a meta-analysis of MDR1/gp170 expression and its possible functional significance) . J Natl Cancer Inst . 1997;89:917–931
  34. Ravdin PM . Anthracycline resistance in breast cancer (clinical applications of current knowledge) . Eur J Cancer . 1995;31A(Suppl 7):S11–S14
  35. Kaye SB . Multidrug resistance in breast cancer—is the jury in yet? . J Natl Cancer Inst . 1997;89:902–903
  36. Nabholtz JM , Crown J . Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens (preliminary results) . Semin Oncol . 1998;25(6 Suppl 13):4–9
  37. Clemons M , Leahy M , Valle J , et al.   Review of recent trials of chemotherapy for advanced breast cancer (the taxanes) . Eur J Cancer . 1997;33:2183–2193
  38. Valero V , Holmes FA , Walters RS , et al.   Phase II trial of docetaxel (a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer) . J Clin Oncol . 1995;13:2886–2894
  39. Bear HD , Anderson S , Brown A , et al.   The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide (preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27) . J Clin Oncol . 2003;21:4165–4174
  40. Newman LA , Buzdar AU , Singletary SE , et al.   A prospective trial of preoperative chemotherapy in resectable breast cancer (predictors of breast-conservation therapy feasibility) . Ann Surg Oncol . 2002;9:228–234
  41. Smith IC , Heys SD , Hutcheon AW , et al.   Neoadjuvant chemotherapy in breast cancer (significantly enhanced response with docetaxel) . J Clin Oncol . 2002;20:1456–1466
  42. Hutcheon AW , Heys SD , Sarkar TK . Neoadjuvant docetaxel in locally advanced breast cancer . Breast Cancer Res Treat . 2003;79(Suppl 1):S19–S24
  43. Abstracts of the 26th Annual San Antonio Breast Cancer Symposium. December 3-6, 2003 . Breast Cancer Res Treat . 2003;82(Suppl 1):1–195
  44. Nason KS , Anderson BO , Byrd DR , et al.   Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma . Cancer . 2000;89:2187–2194
  45. Breslin TM , Cohen L , Sahin A , et al.   Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer . J Clin Oncol . 2000;18:3480–3486
  46. Onda M , Emi M , Nagai H , et al.   Gene expression patterns as marker for 5-year postoperative prognosis of primary breast cancers . J Cancer Res Clin Oncol . 2004;130:537–545
  47. Paik S , Shak S , Tang G , et al.   A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer . N Engl J Med . 2004;351:2817–2826
  48. Muller JM , Erasmi H , Stelzner M , et al.   Surgical therapy of oesophageal carcinoma . Br J Surg . 1990;77:845–857
  49. Ajani JA . Preoperative therapy for patients with resectable squamous cell carcinoma of the esophagus (are we still confused?) . Ann Surg Oncol . 2002;9:605–606
  50. Urschel JD , Vasan H , Blewett CJ . A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer . Am J Surg . 2002;183:274–279
  51. Urschel JD , Vasan H . A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer . Am J Surg . 2003;185:538–543
  52. Nygaard K , Hagen S , Hansen HS , et al.   Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer . World J Surg . 1992;16:1104–1109 discussion 1110.
  53. Arnott SJ , Duncan W , Kerr GR , et al.   Low dose preoperative radiotherapy for carcinoma of the oesophagus (results of a randomized clinical trial) . Radiother Oncol . 1992;24:108–113
  54. Wang M , Gu XZ , Yin WB , et al.   Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma (report on 206 patients) . Int J Radiat Oncol Biol Phys . 1989;16:325–327
  55. Iizuka T , Ide H , Kakegawa T , et al.   Preoperative radioactive therapy for esophageal carcinoma. Randomized evaluation trial in eight institutions . Chest . 1988;93:1054–1058
  56. Launois B , Delarue D , Campion JP , Kerbaol M . Preoperative radiotherapy for carcinoma of the esophagus . Surg Gynecol Obstet . 1981;153:690–692
  57. Kaklamanos IG , Walker GR , Ferry K , et al.   Neoadjuvant treatment for resectable cancer of the esophagus and the gastroesophageal junction (a meta-analysis of randomized clinical trials) . Ann Surg Oncol . 2003;10:754–761
  58. Daly JM , Fry WA , Little AG , et al.   Esophageal cancer (results of an American College of Surgeons Patient Care Evaluation Study) . J Am Coll Surg . 2000;190:562–572 discussion 572-3.
  59. Arnott SJ , Duncan W , Gignoux M , et al.  Oesophageal Cancer Collaborative Group   Preoperative radiotherapy for esophageal carcinoma . Cochrane Database Syst Rev . 2000;2: CD001799
  60. Roth JA , Pass HI , Flanagan MM , et al.   Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus . J Thorac Cardiovasc Surg . 1988;96:242–248
  61. Schlag PM  The Chirurgische Arbeitsgemeinschaft Fuer Onkologie der Deutschen Gesellschaft Fuer Chirurgie Study Group . Randomized trial of preoperative chemotherapy for squamous cell cancer of the esophagus . Arch Surg . 1992;127:1446–1450
  62. Maipang T , Vasinanukorn P , Petpichetchian C , et al.   Induction chemotherapy in the treatment of patients with carcinoma of the esophagus . J Surg Oncol . 1994;56:191–197
  63. Kelsen DP , Ginsberg R , Pajak TF , et al.   Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer . N Engl J Med . 1998;339:1979–1984
  64. Ancona E , Ruol A , Santi S , et al.   Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma (final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone) . Cancer . 2001;91:2165–2174
  65. Medical Research Council Oesophageal Cancer Working Group . Surgical resection with or without preoperative chemotherapy in oesophageal cancer (a randomised controlled trial) . Lancet . 2002;359:1727–1733
  66. Law S , Fok M , Chow S , et al.   Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus (a prospective randomized trial) . J Thorac Cardiovasc Surg . 1997;114:210–217
  67. Blot WJ , Devesa SS , Kneller RW , Fraumeni JF . Rising incidence of adenocarcinoma of the esophagus and gastric cardia . JAMA . 1991;265:1287–1289
  68. Posner MC , Gooding WE , Lew JI , et al.   Complete 5-year follow-up of a prospective phase II trial of preoperative chemoradiotherapy for esophageal cancer . Surgery . 2001;130:620–626 discussion 626-8.
  69. Apinop C , Puttisak P , Preecha N . A prospective study of combined therapy in esophageal cancer . Hepatogastroenterology . 1994;41:391–393
  70. Urba SG , Orringer MB , Turrisi A , et al.   Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma . J Clin Oncol . 2001;19:305–313
  71. Kelsen D . Preoperative chemoradiotherapy for esophageal cancer . J Clin Oncol . 2001;19:283–285
  72. Walsh TN , Noonan N , Hollywood D , et al.   A comparison of multimodal therapy and surgery for esophageal adenocarcinoma . N Engl J Med . 1996;335:462–467
  73. Kim HJ , Bains MS . Randomized clinical trials in esophageal cancer . Surg Oncol Clin N Am . 2002;11:89–109 viii.
  74. Bosset JF , Gignoux M , Triboulet JP , et al.   Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus . N Engl J Med . 1997;337:161–167
  75. Vogel SB , Mendenhall WM , Sombeck MD , et al.   Downstaging of esophageal cancer after preoperative radiation and chemotherapy . Ann Surg . 1995;221:685–693 discussion 693-5.
  76. Yeh AM , Mendenhall WM , Morris CG , et al.   Factors predictive of survival for esophageal carcinoma treated with preoperative radiotherapy with or without chemotherapy followed by surgery . J Surg Oncol . 2003;83:14–23
  77. Abdalla EK , Pisters PW . Staging and preoperative evaluation of upper gastrointestinal malignancies . Semin Oncol . 2004;31:513–529
  78. Michiels S , Koscielny S , Hill C . Prediction of cancer outcome with microarrays (a multiple random validation strategy) . Lancet . 2005;365:488–492
  79. Le Prise E , Etienne PL , Meunier B , et al.   A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus . Cancer . 1994;73:1779–1784
  80. Gibson MK , Abraham SC , Wu TT , et al.   Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy . Clin Cancer Res . 2003;9:6461–6468
  81. Hirai T , Kawano K , Hirabayashi N , et al.   A novel in vitro chemosensitivity test using materials collected by endoscopic biopsy . Anticancer Drugs . 1991;2:269–274
  82. Segalin A , Ruol A , Panozzo M , et al.   Flow cytometric DNA analysis does not predict the radiochemoresponsiveness of esophageal cancer . J Surg Oncol . 1993;54:87–90
  83. Ajani JA , Faust J , Yao J , et al.   Irinotecan/cisplatin followed by 5-FU/paclitaxel/radiotherapy and surgery in esophageal cancer . Oncology (Huntingt) . 2003;17(9 Suppl 8):20–22
  84. Ajani JA , Walsh G , Komaki R , et al.   Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction . Cancer . 2004;100:2347–2354
  85. Darnton SJ , Archer VR , Stocken DD , et al.   Preoperative mitomycin, ifosfamide, and cisplatin followed by esophagectomy in squamous cell carcinoma of the esophagus (pathologic complete response induced by chemotherapy leads to long-term survival) . J Clin Oncol . 2003;21:4009–4015
  86. Leichman L . Cancer of the esophagus (the Wayne State University experience) . Invest New Drugs . 1989;7:91–100
  87. Urba SG , Orringer MB , Ianettonni M , et al.   Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma . Cancer . 2003;98:2177–2183
  88. Meluch AA , Greco FA , Gray JR , et al.   Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer (final results of a Minnie Pearl Cancer Research Network phase II trial) . Cancer J . 2003;9:251–260
  89. Abdel-Latif MM , O’Riordan J , Windle HJ , et al.   NF-kappaB activation in esophageal adenocarcinoma (relationship to Barrett’s metaplasia, survival, and response to neoadjuvant chemoradiotherapy) . Ann Surg . 2004;239:491–500
  90. Kitamura K , Kuwano H , Watanabe M , et al.   Prospective randomized study of hyperthermia combined with chemoradiotherapy for esophageal carcinoma . J Surg Oncol . 1995;60:55–58
  91. Sugimachi K , Kitamura K , Baba K , et al.   Hyperthermia combined with chemotherapy and irradiation for patients with carcinoma of the oesophagus—a prospective randomized trial . Int J Hyperthermia . 1992;8:289–295
  92. Sugimachi K , Kuwano H , Ide H , et al.   Chemotherapy combined with or without hyperthermia for patients with oesophageal carcinoma (a prospective randomized trial) . Int J Hyperthermia . 1994;10:485–493
  93. Niederhuber JE . Neoadjuvant therapy . Ann Surg . 1999;229:309–312
  94. Hayes N , Wayman J , Wadehra V , et al.   Peritoneal cytology in the surgical evaluation of gastric carcinoma . Br J Cancer . 1999;79(3-4):520–524
  95. Lordick F , Stein HJ , Peschel C , Siewert JR . Neoadjuvant therapy for oesophagogastric cancer . Br J Surg . 2004;91:540–551
  96. Wilke H , Preusser P , Fink U , et al.   Preoperative chemotherapy in locally advanced and nonresectable gastric cancer (a phase II study with etoposide, doxorubicin, and cisplatin) . J Clin Oncol . 1989;7:1318–1326
  97. Schuhmacher CP , Fink U , Becker K , et al.   Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up . Cancer . 2001;91:918–927
  98. Findlay M , Cunningham D , Norman A , et al.   A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF) . Ann Oncol . 1994;5:609–616
  99. Kelsen D , Karpeh M , Schwartz G , et al.   Neoadjuvant therapy of high-risk gastric cancer (a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil) . J Clin Oncol . 1996;14:1818–1828
  100. Crookes P , Leichman CG , Leichman L , et al.   Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy (a final report) . Cancer . 1997;79:1767–1775
  101. Lowy AM , Feig BW , Janjan N , et al.   A pilot study of preoperative chemoradiotherapy for resectable gastric cancer . Ann Surg Oncol . 2001;8:519–524
  102. Nio Y , Koike M , Omori H , et al.   A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil (UFT) for gastric cancer—a single institute study . Anticancer Res . 2004;24:1879–1887
  103. Yano M , Yasuda T , Fujiwara Y , et al.   Preoperative intraperitoneal chemotherapy for patients with serosa-infiltrating gastric cancer . J Surg Oncol . 2004;88:39–43
  104. Lowy AM , Mansfield PF , Leach SD , et al.   Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer . Ann Surg . 1999;229:303–308
  105. Ajani JA , Mansfield PF , Janjan N , et al.   Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma . J Clin Oncol . 2004;22:2774–2780
  106. Ajani JA , Mansfield PF , Crane CH , et al.   Paclitaxel-based chemoradiotherapy in localized gastric carcinoma (degree of pathologic response and not clinical parameters dictated patient outcome) . J Clin Oncol . 2005;23:1237–1244
  107. Hartgrink HH , van de Velde CJ , Putter H , et al.   Neo-adjuvant chemotherapy for operable gastric cancer (long term results of the Dutch randomised FAMTX trial) . Eur J Surg Oncol . 2004;30:643–649
  108. Allum W , Cunningham D , Weeden S . Perioperative chemotherapy in operable gastric and lower esophageal cancer. A randomised controlled trial (the MAGIC trial ISRCTN 93793971) . (abstract) Proc Am Soc Clin Oncol . 2003;21:998
  109. Gochi A , Orita K , Fuchimoto S , et al.   The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients . Br J Cancer . 2001;84:443–451
  110. Sun W , Haller DG . Recent advances in the treatment of gastric cancer . Drugs . 2001;61:1545–1551
  111. Ott K , Vogelsang H , Mueller J , et al.   Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma . Clin Cancer Res . 2003;9:2307–2315
  112. Boku N , Chin K , Hosokawa K , et al.   Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum . Clin Cancer Res . 1998;4:1469–1474
  113. Macdonald JS , Smalley SR , Benedetti J , et al.   Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction . N Engl J Med . 2001;345:725–730
  114. Sohn TA , Yeo CJ , Cameron JL , et al.   Resected adenocarcinoma of the pancreas-616 patients (results, outcomes, and prognostic indicators) . J Gastrointest Surg . 2000;4:567–579
  115. Kalser MH , Ellenberg SS . Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection . Arch Surg . 1985;120:899–903
  116. Klinkenbijl JH , Jeekel J , Sahmoud T , et al.   Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region (phase III trial of the EORTC gastrointestinal tract cancer cooperative group) . Ann Surg . 1999;230:776–782 discussion 782-4.
  117. Hoffman JP . Adjuvant therapy of pancreatic adenocarcinoma . Surg Oncol Clin N Am . 2004;13:XV–XVI
  118. Evans DB , Rich TA , Byrd DR , et al.   Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas . Arch Surg . 1992;127:1335–1339
  119. Spitz FR , Abbruzzese JL , Lee JE , et al.   Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas . J Clin Oncol . 1997;15:928–937
  120. Staley CA , Lee JE , Cleary KR , et al.   Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head . Am J Surg . 1996;171:118–124 discussion 124-5.
  121. Pisters PW , Abbruzzese JL , Janjan NA , et al.   Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma . J Clin Oncol . 1998;16:3843–3850
  122. Breslin TM , Hess KR , Harbison DB , et al.   Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas (treatment variables and survival duration) . Ann Surg Oncol . 2001;8:123–132
  123. Hoffman JP , Weese JL , Solin LJ , et al.   A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma . Am Surg . 1993;59:772–780 discussion 780-1.
  124. Hoffman JP , Weese JL , Solin LJ , et al.   A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas . Am J Surg . 1995;169:71–77 discussion 77-8.
  125. Hoffman JP , Lipsitz S , Pisansky T , et al.   Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas (an Eastern Cooperative Oncology Group Study) . J Clin Oncol . 1998;16:317–323
  126. Arnoletti JP , Hoffman JP , Ross EA , et al.   Preoperative chemoradiation in the management of adenocarcinoma of the body of the pancreas . Am Surg . 2002;68:330–335 discussion 335-6.
  127. 58th Annual Cancer Symposium, Society of Surgical Oncology, March 3-6, 2005, Atlanta, Georgia, USA . Abstracts Ann Surg Oncol . 2005;12(2 Suppl):8–109
  128. Pisters PW , Wolff RA , Janjan NA , et al.   Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma (toxicities, histologic response rates, and event-free outcome) . J Clin Oncol . 2002;20:2537–2544
  129. Kim HJ , Czischke K , Brennan MF , Conlon KC . Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? . J Gastrointest Surg . 2002;6:763–769
  130. Mendenhall WM , Rout WR , Lind DS , et al.   Role of radiation therapy in the treatment of resectable rectal adenocarcinoma . J Surg Oncol . 2002;79:107–117 discussion 118.
  131. Heald RJ . A new approach to rectal cancer . Br J Hosp Med . 1979;22:277–281
  132. Gastrointestinal Tumor Study Group . Prolongation of the disease-free interval in surgically treated rectal carcinoma . N Engl J Med . 1985;312:1465–1472
  133. O’Connell MJ , Martenson JA , Wieand HS , et al.   Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery . N Engl J Med . 1994;331:502–507
  134. Krook JE , Moertel CG , Gunderson LL , et al.   Effective surgical adjuvant therapy for high-risk rectal carcinoma . N Engl J Med . 1991;324:709–715
  135. Mendenhall WM , Bland KI , Copeland EM , et al.   Does preoperative radiation therapy enhance the probability of local control and survival in high-risk distal rectal cancer? . Ann Surg . 1992;215:696–705 discussion 705-6.
  136. Wolmark N , Wieand HS , Hyams DM , et al.   Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum (National Surgical Adjuvant Breast and Bowel Project Protocol R-02) . J Natl Cancer Inst . 2000;92:388–396
  137. NIH consensus conference . Adjuvant therapy for patients with colon and rectal cancer . JAMA . 1990;264:1444–1450
  138. Lim CS , Mehigan BJ , Hartley JE , Monson JR . Neoadjuvant therapy in the treatment of high risk rectal carcinoma . Surg Oncol . 1999;8:1–11
  139. Stockholm Colorectal Cancer Study Group . Randomized study on preoperative radiotherapy in rectal carcinoma . Ann Surg Oncol . 1996;3:423–430
  140. Gerard A , Buyse M , Nordlinger B , et al.   Preoperative radiotherapy as adjuvant treatment in rectal cancer. Final results of a randomized study of the European Organization for Research and Treatment of Cancer (EORTC) . Ann Surg . 1988;208:606–614
  141. Pahlman L , Glimelius B , Graffman S . Pre- versus postoperative radiotherapy in rectal carcinoma (an interim report from a randomized multicentre trial) . Br J Surg . 1985;72:961–966
  142. Heidelberger C , Griesbach L , Montag BJ , et al.   Studies on fluorinated pyrimidines. II. Effects on transplanted tumors . Cancer Res . 1958;18:305–317
  143. Byfield JE , Calabro-Jones P , Klisak I , Kulhanian F . Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and x rays . Int J Radiat Oncol Biol Phys . 1982;8:1923–1933
  144. Frykholm GJ , Glimelius B , Pahlman L . Preoperative or postoperative irradiation in adenocarcinoma of the rectum (final treatment results of a randomized trial and an evaluation of late secondary effects) . Dis Colon Rectum . 1993;36:564–572
  145. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial . N Engl J Med . 1997;336:980–987
  146. Kapiteijn E , Marijnen CA , Nagtegaal ID , et al.   Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer . N Engl J Med . 2001;345:638–646
  147. Marsh RD , Chu NM , Vauthey JN , et al.   Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy . Cancer . 1996;78:217–225
  148. Minsky BD , Cohen AM , Kemeny N , et al.   Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy . J Clin Oncol . 1992;10:79–84
  149. Mendenhall WM , Vauthey JN , Zlotecki RA , et al.   Preoperative chemoradiation for locally advanced rectal adenocarcinoma—the University of Florida experience . Semin Surg Oncol . 2003;21:261–264
  150. Minsky BD , Kemeny N , Cohen AM , et al.   Preoperative high-dose leucovorin/5-fluorouracil and radiation therapy for unresectable rectal cancer . Cancer . 1991;67:2859–2866
  151. Minsky BD , Cohen AM , Kemeny N , et al.   The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer . Cancer . 1993;71:3486–3492
  152. Minsky BD , Cohen AM , Kemeny N , et al.   Combined modality therapy of rectal cancer (decreased acute toxicity with the preoperative approach) . J Clin Oncol . 1992;10:1218–1224
  153. Minsky BD , Cohen AM , Enker WE , et al.   Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer . Int J Radiat Oncol Biol Phys . 1997;37:289–295
  154. Frykholm G , Glimelius B , Pahlman L . Preoperative irradiation with and without chemotherapy (MFL) in the treatment of primarily non-resectable adenocarcinoma of the rectum. Results from two consecutive studies . Eur J Cancer Clin Oncol . 1989;25:1535–1541
  155. Frykholm GJ , Pahlman L , Glimelius B . Combined chemo- and radiotherapy vs. radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum . Int J Radiat Oncol Biol Phys . 2001;50:427–434
  156. Bosset JF , Magnin V , Maingon P , et al.   Preoperative radiochemotherapy in rectal cancer (long-term results of a phase II trial) . Int J Radiat Oncol Biol Phys . 2000;46:323–327
  157. Bosset JF , Calais G , Daban A , et al.   Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group . Eur J Cancer . 2004;40:219–224
  158. Bosset JF , Calais G , Mineur L , et al.   Enhanced Tumorocidal Effect of Preoperative Radiotherapy on Rectal Cancer by Adding Chemotherapy (Preliminary Results from the 22921 European Organisation for Research and Treatment of Cancer Randomized Trial) . J Clin Oncol . 2005;23:5620–5627
  159. Sauer R , Becker H , Hohenberger W , et al.   Preoperative versus postoperative chemoradiotherapy for rectal cancer . N Engl J Med . 2004;351:1731–1740
  160. Sauer R . Adjuvant versus neoadjuvant combined modality treatment for locally advanced rectal cancer (first results of the German rectal cancer study (CAO/ARO/AIO-94)) . Int J Radiat Oncol Biol Phys . 2003;57(2 Suppl):S124–S125
  161. Reerink O , Verschueren RC , Szabo BG , et al.   A favourable pathological stage after neoadjuvant radiochemotherapy in patients with initially irresectable rectal cancer correlates with a favourable prognosis . Eur J Cancer . 2003;39:192–195
  162. Meade PG , Blatchford GJ , Thorson AG , et al.   Preoperative chemoradiation downstages locally advanced ultrasound-staged rectal cancer . Am J Surg . 1995;170:609–612 discussion 612-3.
  163. Valero G , Lujan JA , Hernandez Q , et al.   Neoadjuvant radiation and chemotherapy in rectal cancer does not increase postoperative complications . Int J Colorectal Dis . 2003;18:495–499
  164. Heald RJ . Total mesorectal excision is optimal surgery for rectal cancer (a Scandinavian consensus) . Br J Surg . 1995;82:1297–1299
  165. Nigro ND , Seydel HG , Considine B , et al.   Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal . Cancer . 1983;51:1826–1829
  166. UKCCCR Anal Cancer Trial Working Party UK Co-ordinating Committee on Cancer Research . Epidermoid anal cancer (results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin) . Lancet . 1996;348:1049–1054
  167. Nigro ND . An evaluation of combined therapy for squamous cell cancer of the anal canal . Dis Colon Rectum . 1984;27:763–766
  168. Kunkler PB , Das RN . Radiotherapy of anal carcinoma . Proc R Soc Med . 1968;61:628–629
  169. Childs DS , Moertel CG , Holbrook MA , et al.   Treatment of unresectable adenocarcinomas of the stomach with a combination of 5-fluorouracil and radiation . Am J Roentgenol Radium Ther Nucl Med . 1968;102:541–544
  170. Vietti T , Eggerding F , Valeriote F . Combined effect of x radiation and 5-fluorouracil on survival of transplanted leukemic cells . J Natl Cancer Inst . 1971;47:865–870
  171. Lelieveld P , Smink T , van Putten L . Experimental studies on the combination of radiation and chemotherapy . Int J Radiat Oncol Biol Phys . 1978;4(1-2):37–41
  172. Looney WB , Hopkins HA , MacLeod MS , Ritenour R . Solid tumor models for the assessment of different treatment modalities. XII. Combined chemotherapy-radiotherapy: variation of time interval between time of administration of 5-fluorouracil and radiation and its effect on the control of tumor growth . Cancer . 1979;44:437–445
  173. Nigro ND , Vaitkevicius VK , Considine B . Combined therapy for cancer of the anal canal (a preliminary report) . Dis Colon Rectum . 1974;17:354–356
  174. Nigro ND . The force of change in the management of squamous-cell cancer of the anal canal . Dis Colon Rectum . 1991;34:482–486
  175. Moore HG , Guillem JG . Anal neoplasms . Surg Clin North Am . 2002;82:1233–1251
  176. Flam M , John M , Pajak TF , et al.   Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal (results of a phase III randomized intergroup study) . J Clin Oncol . 1996;14:2527–2539
  177. Bartelink H , Roelofsen F , Eschwege F , et al.   Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer (results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups) . J Clin Oncol . 1997;15:2040–2049
  178. Ferguson PJ , Collins O , Dean NM , et al.   Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells . Br J Pharmacol . 1999;127:1777–1786
  179. Dorr RT , Bowden GT , Alberts DS , Liddil JD . Interactions of mitomycin C with mammalian DNA detected by alkaline elution . Cancer Res . 1985;45:3510–3516
  180. Sartorelli AC , Hodnick WF , Belcourt MF , et al.   Mitomycin C (a prototype bioreductive agent) . Oncol Res . 1994;6(10-11):501–508
  181. Klas JV , Rothenberger DA , Wong WD , Madoff RD . Malignant tumors of the anal canal (the spectrum of disease, treatment, and outcomes) . Cancer . 1999;85:1686–1693
  182. Papagikos M , Crane CH , Skibber J , et al.   Chemoradiation for adenocarcinoma of the anus . Int J Radiat Oncol Biol Phys . 2003;55:669–678
  183. Jensen SL , Shokouh-Amiri MH , Hagen K , et al.   Adenocarcinoma of the anal ducts. A series of 21 cases . Dis Colon Rectum . 1988;31:268–272
  184. Basik M , Rodriguez-Bigas MA , Penetrante R , Petrelli NJ . Prognosis and recurrence patterns of anal adenocarcinoma . Am J Surg . 1995;169:233–237
  185. Billingsley KG , Stern LE , Lowy AM , et al.   Uncommon anal neoplasms . Surg Oncol Clin N Am . 2004;13:375–388
  186. Schaffzin DM , Stahl TJ , Smith LE . Perianal mucinous adenocarcinoma (unusual case presentations and review of the literature) . Am Surg . 2003;69:166–169
  187. Beal KP , Wong D , Guillem JG , et al.   Primary adenocarcinoma of the anus treated with combined modality therapy . Dis Colon Rectum . 2003;46:1320–1324
  188. Newlin HE , Zlotecki RA , Morris CG , et al.   Squamous cell carcinoma of the anal margin . J Surg Oncol . 2004;86:55–62 discussion 63.
  189. Peiffert D , Giovannini M , Ducreux M , et al.   High-dose radiation therapy and neoadjuvant plus concomitant chemotherapy with 5-fluorouracil and cisplatin in patients with locally advanced squamous-cell anal canal cancer (final results of a phase II study) . Ann Oncol . 2001;12:397–404
  190. Hung A , Crane C , Delclos M , et al.   Cisplatin-based combined modality therapy for anal carcinoma (a wider therapeutic index) . Cancer . 2003;97:1195–1202
  191. Nathanson DR , Thomas CR , Bleday R . Recent clinical trials summary . Surg Oncol Clin N Am . 2004;13:389–394
  192. Kapp KS , Geyer E , Gebhart FH , et al.   Experience with split-course external beam irradiation +/− chemotherapy and integrated Ir-192 high-dose-rate brachytherapy in the treatment of primary carcinomas of the anal canal . Int J Radiat Oncol Biol Phys . 2001;49:997–1005
  193. Bosset JF , Roelofsen F , Morgan DA , et al.  Radiotherapy and Gastrointestinal Cooperative Groups   Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer . Eur J Cancer . 2003;39:45–51
  194. Frisch M , Glimelius B , van den Brule AJ , et al.   Sexually transmitted infection as a cause of anal cancer . N Engl J Med . 1997;337:1350–1358
  195. Chu NR , Wu HB , Wu T , et al.   Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7 . Clin Exp Immunol . 2000;121:216–225
  196. Klencke B , Matijevic M , Urban RG , et al.   Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia (a phase I study of ZYC101) . Clin Cancer Res . 2002;8:1028–1037
  197. Rajdev L , Keller SM . Neoadjuvant and adjuvant therapy of non-small cell lung cancer . Surg Oncol . 2002;11:243–253
  198. Jaklitsch MT , Strauss GM , Healey EA , et al.   An historical perspective of multi-modality treatment for resectable non-small cell lung cancer . Lung Cancer . 1995;12(Suppl 2):S17–S32
  199. Murren JR , Buzaid AC , Hait WN . Critical analysis of neoadjuvant therapy for Stage IIIa non-small cell lung cancer [corrected] . Am Rev Respir Dis . 1991;143(4 Pt 1):889–894
  200. Depierre A , Westeel V , Jacoulet P . Preoperative chemotherapy for non-small cell lung cancer . Cancer Treat Rev . 2001;27:119–127
  201. Pisters KM , Ginsberg RJ , Giroux DJ , et al.  Bimodality Lung Oncology Team   Induction chemotherapy before surgery for early-stage lung cancer (a novel approach) . J Thorac Cardiovasc Surg . 2000;119:429–439
  202. Martini N , Kris MG , Flehinger BJ , et al.   Preoperative chemotherapy for stage IIIa (N2) lung cancer (the Sloan-Kettering experience with 136 patients) . Ann Thorac Surg . 1993;55:1365–1373 discussion 1373-4.
  203. Burkes RL , Ginsberg RJ , Shepherd FA , et al.   Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer (results of the Toronto Phase II Trial) . J Clin Oncol . 1992;10:580–586
  204. Elias AD , Skarin AT , Leong T , et al.   Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC) . Lung Cancer . 1997;17:147–161
  205. Roth JA , Fossella F , Komaki R , et al.   A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer . J Natl Cancer Inst . 1994;86:673–680
  206. Roth JA , Atkinson EN , Fossella F , et al.   Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer . Lung Cancer . 1998;21:1–6
  207. Rosell R , Gomez-Codina J , Camps C , et al.   A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer . N Engl J Med . 1994;330:153–158
  208. Rosell R , Gomez-Codina J , Camps C , et al.   Preresectional chemotherapy in stage IIIA non-small-cell lung cancer (a 7-year assessment of a randomized controlled trial) . Lung Cancer . 1999;26:7–14
  209. Albain KS , Rusch VW , Crowley JJ , et al.   Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer (mature results of Southwest Oncology Group phase II study 8805) . J Clin Oncol . 1995;13:1880–1892
  210. Albain KS , Crowley JJ , Turrisi AT , et al.   Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer (a Southwest Oncology Group phase II study, SWOG 9019) . J Clin Oncol . 2002;20:3454–3460
  211. Eberhardt W , Wilke H , Stamatis G , et al.   Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer (mature results of a phase II trial) . J Clin Oncol . 1998;16:622–634
  212. Lee SW , Choi EK , Lee JS , et al.   Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for stage III locally advanced, unresectable, non-small-cell lung cancer . Int J Radiat Oncol Biol Phys . 2003;56:996–1004
  213. Trodella L , Granone P , Valente S , et al.   Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non-small-cell lung cancer (long-term results according to downstaging) . Ann Oncol . 2004;15:389–398
  214. Machtay M , Lee JH , Stevenson JP , et al.   Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma (long-term results and associations with pathologic response) . J Thorac Cardiovasc Surg . 2004;127:108–113
  215. Skarin A , Jochelson M , Sheldon T , et al.   Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer (long-term follow-up in 41 patients) . J Surg Oncol . 1989;40:266–274
  216. Faber LP , Kittle CF , Warren WH , et al.   Preoperative chemotherapy and irradiation for stage III non-small cell lung cancer . Ann Thorac Surg . 1989;47:669–675 discussion 676-7.
  217. Kirn DH , Lynch TJ , Mentzer SJ , et al.   Multimodality therapy of patients with stage IIIA, N2 non-small-cell lung cancer. Impact of preoperative chemotherapy on resectability and downstaging . J Thorac Cardiovasc Surg . 1993;106:696–702
  218. Choi NC , Carey RW , Daly W , et al.   Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer . J Clin Oncol . 1997;15:712–722
  219. Eberhardt W , Bildat S , Korfee S , Stamatis G . Preoperative treatment strategies in stage III non-small cell lung cancer . Lung Cancer . 2001;33(Suppl 1):S51–S59
  220. Lynch TJ , Bell DW , Sordella R , et al.   Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib . N Engl J Med . 2004;350:2129–2139
  221. Betticher DC , Hsu Schmitz SF , Totsch M , et al.   Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer (a multicenter phase II trial) . J Clin Oncol . 2003;21:1752–1759
  222. Van Zandwijk N , Smit EF , Kramer GW , et al.   Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer (a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955)) . J Clin Oncol . 2000;18:2658–2664
  223. Cance WG , Liu ET . Protein kinases in human breast cancer . Breast Cancer Res Treat . 1995;35:105–114
  224. Cance WG , Harris JE , Iacocca MV , et al.   Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues (correlation with preinvasive and invasive phenotypes) . Clin Cancer Res . 2000;6:2417–2423
  225. Lark AL , Livasy CA , Calvo B , et al.   Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases (immunohistochemistry and real-time PCR analyses) . Clin Cancer Res . 2003;9:215–222
  226. Eberhardt WE , Albain KS , Pass H , et al.   Induction treatment before surgery for non-small cell lung cancer . Lung Cancer . 2003;42(Suppl 1):S9–S14
  227. Pisters PW , Ballo MT , Patel SR . Preoperative chemoradiation treatment strategies for localized sarcoma . Ann Surg Oncol . 2002;9:535–542
  228. Goodnight JE , Bargar WL , Voegeli T , Blaisdell FW . Limb-sparing surgery for extremity sarcomas after preoperative intraarterial doxorubicin and radiation therapy . Am J Surg . 1985;150:109–113
  229. Levine EA , Trippon M , Das Gupta TK . Preoperative multimodality treatment for soft tissue sarcomas . Cancer . 1993;71:3685–3689
  230. Temple WJ , Temple CL , Arthur K , et al.   Prospective cohort study of neoadjuvant treatment in conservative surgery of soft tissue sarcomas . Ann Surg Oncol . 1997;4:586–590
  231. Wanebo HJ , Temple WJ , Popp MB , et al.   Preoperative regional therapy for extremity sarcoma. A tricenter update . Cancer . 1995;75:2299–2306
  232. Eilber F , Eckardt J , Rosen G , et al.   Preoperative therapy for soft tissue sarcoma . Hematol Oncol Clin North Am . 1995;9:817–823
  233. Pisters PW , Patel SR , Prieto VG , et al.   Phase I trial of preoperative doxorubicin-based concurrent chemoradiation and surgical resection for localized extremity and body wall soft tissue sarcomas . J Clin Oncol . 2004;22:3375–3380
  234. Eilber FC , Rosen G , Eckardt J , et al.   Treatment-induced pathologic necrosis (a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas) . J Clin Oncol . 2001;19:3203–3209
  235. Goffman T , Tochner Z , Glatstein E . Primary treatment of large and massive adult sarcomas with iododeoxyuridine and aggressive hyperfractionated irradiation . Cancer . 1991;67:572–576
  236. Sondak VK , Robertson JM , Sussman JJ , et al.   Preoperative idoxuridine and radiation for large soft tissue sarcomas (clinical results with five-year follow-up) . Ann Surg Oncol . 1998;5:106–112
  237. Sauer R , Schuchardt U , Hohenberger W , et al.   [Neoadjuvant radiochemotherapy in soft tissue sarcomas. Optimization of local functional tumor control] . Strahlenther Onkol . 1999;175:259–266
  238. Cormier JN , Patel SR , Herzog CE , et al.   Concurrent ifosfamide-based chemotherapy and irradiation. Analysis of treatment-related toxicity in 43 patients with sarcoma . Cancer . 2001;92:1550–1555
  239. Eilber FC , Eilber FR , Eckardt J , et al.   The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma . Ann Surg . 2004;240:686–695 discussion 695-7.
  240. DeLaney TF , Spiro IJ , Suit HD , et al.   Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas . Int J Radiat Oncol Biol Phys . 2003;56:1117–1127
  241. O’Sullivan B , Davis AM , Turcotte R , et al.   Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs (a randomised trial) . Lancet . 2002;359:2235–2241
  242. Hartford AC , Gohongi T , Fukumura D , Jain RK . Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site (potential role of host-tumor interaction) . Cancer Res . 2000;60:2128–2131
  243. Schlemmer M , Wendtner CM , Issels RD . Ifosfamide with regional hyperthermia in soft-tissue sarcomas . Oncology . 2003;65(Suppl 2):76–79
  244. Dewey WC . Interaction of heat with radiation and chemotherapy . Cancer Res . 1984;44(10 Suppl):4714s–4720s
  245. Lewis JJ , Leung D , Woodruff JM , Brennan MF . Retroperitoneal soft-tissue sarcoma (analysis of 500 patients treated and followed at a single institution) . Ann Surg . 1998;228:355–365
  246. Robertson JM , Sondak VK , Weiss SA , et al.   Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas . Int J Radiat Oncol Biol Phys . 1995;31:87–92
  247. Pisters PW , Harrison LB , Leung DH , et al.   Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma . J Clin Oncol . 1996;14:859–868
  248. Pisters PW , Ballo MT , Fenstermacher MJ , et al.   Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma . J Clin Oncol . 2003;21:3092–3097
  249. Jones JJ , Catton CN , O’Sullivan B , et al.   Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma . Ann Surg Oncol . 2002;9:346–354
  250. Gieschen HL , Spiro IJ , Suit HD , et al.   Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma . Int J Radiat Oncol Biol Phys . 2001;50:127–131
  251. Eisenburg BL , Alektiar K , Ballo M , et al.  Radiation Therapy Oncology Group   Research Plan 2002-2006 . Sarcoma Committee Int J Radiat Oncol Biol Phys . 2001;51(3 Suppl 2):53–55
  252. Dematteo RP , Heinrich MC , El-Rifai WM , Demetri G . Clinical management of gastrointestinal stromal tumors (before and after STI-571) . Hum Pathol . 2002;33:466–477
  253. Joensuu H , Roberts PJ , Sarlomo-Rikala M , et al.   Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor . N Engl J Med . 2001;344:1052–1056
  254. Tuveson DA , Willis NA , Jacks T , et al.   STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein (biological and clinical implications) . Oncogene . 2001;20:5054–5058
  255. Demetri GD , von Mehren M , Blanke CD , et al.   Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors . N Engl J Med . 2002;347:472–480
  256. Brennan MF . Retroperitoneal sarcoma (time for a national trial?) . Ann Surg Oncol . 2002;9:324–325
  257. Sugarbaker DJ , Herndon J , Kohman LJ , et al.  Cancer and Leukemia Group B Thoracic Surgery Group   Results of cancer and leukemia group B protocol 8935. A multi-institutional phase II trimodality trial for stage IIIA (N2) non-small cell lung cancer . J Thorac Cardiovasc Surg . 1995;109:473–483 discussion 483-5.

PII: S0011-3840(06)00047-5

doi: 10.1067/j.cpsurg.2006.04.003

Current Problems in Surgery
Volume 43, Issue 7 , Pages 462-551 , July 2006

Article Tools

* Image Usage & Resolution